
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion is a promising investment opportunity due to its unique approach in targeting beta-cell failure for type 2 diabetes patients with its lead candidate icovamenib, as well as the potential of its BMF-650 GLP agonist for difficult-to-treat diabetics. Their stock is recommended with a Market Outperform rating, as the company is financially stable and has a successful CEO with a history in the biotech industry. Additionally, the company's recent progress in both Phase 2 trials for icovamenib and potential Phase 1 trial for BMF-650 suggests a positive future outlook.
Bears say
Biomea Fusion is a clinical stage company with two key drug candidates, icovamenib and BMF-650, in development for diabetes, obesity, and other metabolic diseases. While Phase 2 data for icovamenib is expected in 4Q26, there are risks associated with data interpretation, as efficacy has been seen in small subgroups and dose-response may not be consistent. Additionally, the market for diabetes medications is crowded and competitive. Therefore, as a financial analyst, I have a negative outlook on Biomea Fusion's stock due to the uncertain potential for its key drug candidates and the challenging market conditions.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares